Clinical trial
Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable…
NCT00006389 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00006389 |
|---|---|
| Title | Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer |
| Official title | A Phase II Combination Trial of Bryostatin-1 and Cisplatin in the Treatment of Metastatic Gastric Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage III Gastric Cancer, Stage IV Gastric Cancer |
| Intervention type | Drug, Other |
| Interventions | bryostatin 1, cisplatin, laboratory biomarker analysis |
| Enrollment | 12 |
| Start date | Oct 1, 2000 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 1, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: